Morgans Under the Microscope: Recent Episodes
Morgans Financial Limited
A series of podcasts that include interviews with executives from ASX-listed companies and updates on the healthcare sector.
Dr Asher Freilich, CEO and founder of the online scripts business InstantScripts explains how concept evolved into a rapidly growing operation with big plans for the future.
Dr James Fielding founder and CEO of Audeara provides an update on the company’s progress.
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU
Healthcare
Rob Wong CEO of Control Bionics provides an update on the company’s progress.
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU
Healthcare
Scott Power, Senior Analyst at Morgans speaks to the Morgans network. He updates on stocks in the Healthcare sector such as: Nanosonics (NAN), Resmed (RMD), Mach 7 (M7T), Impedimed (IPD), Audeara (AUA), Antisense Therapeutics (ANP), Neuren Pharmaceuticals (NEU).
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU
Ralph Highnam CEO and founder of Volpara Health (VHT.ASX) explains the significance of the technology and how its successfully being deployed across many breast clinics.
Peter Rowland MD of Micro-X explains the significance of the next generation X-ray technology for global health and security markets.
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU
X-ray #Security #Healthcare
Morgans healthcare analyst Iain Wilkie talks to Dr James Fielding, CEO of new IPO entrant Audeara (ASX:AUA) on what the company does and where its products fit within the audiology space.
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU
Innovation #Healthcare
Rob Wong Chief Executive Officer of Control Bionics, speaks with Scott Power from the Morgans Healthcare team, providing an update on the significant progress the company is making.
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU
Innovation #Healthcare
Morgans analyst Iain Wilkie speaks with Chief Executive Officer and Managing Director of ResApp (ASX:RAP), Tony Keating. Tony provides an update on a number of recent news events.
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU
Morgans Senior Analysis, Dr. Derek Jellinek, provides an update on the healthcare universe, including key upcoming catalysts.
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU
Healthcare #Stocks #ReportingSeason
Morgans Healthcare Analyst Iain Wilkie talks to Pippa Leary, Chief Executive Officer of Swift Media (ASX:SW1) for a high-level overview of the business, catalysts, and its shift into the large aged care sector.
Scott Power from the Morgans Healthcare team speaks with Peter Rowland, CEO from Micro-X (ASX: MX1) where he explains the technology, its application, and upcoming catalysts for 2021.
Healthcare analysts Iain Wilkie and Scott Power wrap up the week with a review and call out on stocks in the IVF sector such as: Virtus Health (VRT) and Monash IVF Group (MVF). Some other stocks mentioned are ImexHS (IME), Swift Media (SW1), and Impedimed (IPD).
Senior Analyst Scott Power from the Morgans Healthcare team speaks with Jon Pilcher, Chief Executive Officer of Neuren Pharmaceuticals (ASX:NEU). Jon explains a number of key catalysts which are expected in 2021.
Morgans analyst Iain Wilkie discusses the healthcare team's initiation of coverage for Antisense Therapeutics (ASX:ANP) and highlights Neuren Pharmaceuticals (ASX:NEU) as a stock with key catalysts ahead.
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/morgans.australia
On Twitter: twitter.com/morgansAU
Scott Power from the Morgans Healthcare team runs through a number of themes for 2021 together with some upcoming catalysts.
Stocks mentioned include Pro Medicus (PME), Nanosonics (NAN), EBOS Group (EBO), Micro-X (MX1), Impedimed (IPD) Volpara Health Technologies (VHT), and ResMed (RMD).
Check out more from Morgans:
Visit the Morgans website: https://www.morgans.com.au
Check out our blog: https://www.morgans.com.au/Blog
On Facebook: https://www.facebook.com/MorgansAU
On Instagram: https://www.instagram.com/morgans.australia
On Twitter: https://twitter.com/morgansAU
Healthcare #Technology #Morgans
Morgans Analyst Iain Wilkie chats with Claude Solitario, Managing Director of ASX listed mental health technology company Medibio (ASX:MEB). The two chat about an update on a recent partnership as well as a number of upcoming catalysts.
The Morgans Healthcare provides an update on the following companies Promedicus (PME), Nanosonics (NAN), Resmed (RMD), Volpara (VHT), Virtus (VRT), Impedimed (IPD), and Micro-X (MX1)
The Morgans Health team provides an update on the aged care sector and key catalysts achieved (stocks mentioned Micro-X, Impedimed, Virtus, Volpara, Mach 7 and Paradigm)
Morgans analyst Iain Wilkie chats to Dr Sean Hall who is the CEO and MD of drug development company Medlab Clinical (ASX:MDC) on some recent news and upcoming catalysts.
Morgans Senior Analyst Scott Power recaps the healthcare picks for and what to look out for across the current active opportunities.
Some of the companies Scott talks about are: Mach7 Technologies (ASX:M7T), Impedimed (ASX:IPD), Micro-X(ASX:MX1), and Neuron Pharmaceuticals (ASX:NEU).
Morgans Senior Analyst Scott Power recaps the healthcare picks for the week ending in 13, November 2020.
Some of the active opportunities Scott details are Mach7 Technologies (ASX:M7T), Impedimed (ASX:IPD), Micro-X (ASX:MX1), and Neuron Pharmaceuticals (ASX:NEU).
Morgans Analyst Iain Wilkie talks with ResApp (ASX:RAP) CEO, Tony Keating, on a number of recent partnership agreements.
Morgans Senior Analyst, Dr. Derek Jellinek, provides a comprehensive update on the Covid-19 Vaccine. Additionally, Derek breaks down the key stakeholders within the race, and how they are currently positioned.
Neuren Pharmaceuticals’ (ASX:NEU) Chief Executive Officer, Jon Pilcher, sits down with Senior Analyst Scott Power. In this piece, Jon outlines a number of upcoming value drivers for the company.
Morgans Senior Analyst Scott Power notes three upcoming catalysts for Volpara (ASX:VHT) which are likely to move the share price higher.
Morgans Analyst Iain Wilkie recaps the healthcare teams picks for 2020 and what to look out for across the current active opportunities.
Michelle Gallaher, CEO of Opyl Ltd (ASX:OPL) provides an update to the network on what the company does, operational update, a number of new clients, and a potential opportunity ahead.
Morgans analyst Iain Wilkie sat down with Leo Lee, CEO of ASX listed regenerative medicine player Regeneus (ASX:RGS). The two speak on its recent partnership deal for osteoarthritis in Japan and what it means for the company.
Morgans Senior Healthcare Analyst Scott Power highlights four key buys with the Healthcare sector – ResMed (ASX:RMD), Virtus Health (ASX:VRT), EBOS (ASX:EBO) and Nanosonics (ASX:NAN).
Morgans analyst Iain Wilkie runs through a number of healthcare stocks reporting quarterly statements over the week as well as a broader market wrap.
Morgans Analyst Iain Wilkie provides an update on the healthcare market and discusses a some significant swings in a number of micro-cap stocks and highlights two stocks worth watching for the upcoming cashflow reporting season this month.
Morgans Healthcare Analyst Scott Power provides an update on Mach 7 (M7T) following their successful capital raising.
Cochlear (COH) gains FDA’s blessing on multiple products, but nothing appears game-changing.
Bob Proulx CEO of Imagion Biosystems (IBX) provides an update on the company’s progress after it announced plans to start human studies using its MagSense technology.
Morgans Analyst Iain Wilkie talks to CEO of ASX listed regenerative medicine and stem-cell player Regeneus (ASX:RGS) on what the company does and a number of potential catalysts which lie ahead.
ResApp Health (RAP) CEO Tony Keating provides an update on the progression of commercialisation of its diagnostic into the telehealth setting, an update on the SleepCheck product, and outlines a number of key drivers ahead.
Healthcare analyst Iain Wilkie gives another market update and runs through a number of small cap healthcare announcements over the week.
Jon Pilcher CEO of Neuren Pharmaceuticals provides an update on the clinical trials the company is undertaking.
Healthcare analyst Iain Wilkie runs through a number of healthcare announcements over the week and recaps a few trading ideas which have performed strongly over the last few weeks.
Scott Power part of the Morgans Healthcare team provides an update on Volpara after successfully completing its capital raising.
Morgans Senior Analyst Derek Jellinek discusses RMD 3Q results and strong resilience shown across the core business and incremental gains from COVID-19 induced demand for ventilators.
Healthcare analyst Iain Wilkie runs through some market news, a number of updates for stocks under coverage, and some comments on the relaxation of a number of elective medical procedures announced over the week.
Morgans Senior Analyst Scott Power updates the network with information on 3 companies: Volpara (ASX:VHT), Impedimed (ASX:IPD) and Micro-X (ASX:MX1).
Morgans Research Analyst Iain Wilkie talks with Michelle Gallaher, CEO of Opyl Limited (#ASX : $OPL). Michelle gives a recap on a number of products coming to market, a new partner to expand its reach, and what potential investors can look out for.
Morgans Research Analyst Iain Wilkie talks with Mark Diamond, Managing Director of Antisense Therapeutics (ASX:ANP). Mark shares a recap on what the company does, and what potential investors can look out for.
Morgans Senior Analyst Scott Power, close out on the week that was 3/04/2020. He shares an update on the Healthcare sector and run through a couple of stocks to look out for.
Morgans Analyst Iain Wilkie and Senior Analyst Scott Power, close out on the week that was 20/03/2020. They run through another tough week on the market, and provide an update on some of their stocks under coverage.
Morgans Analyst Iain Wilkie and Senior Analyst Scott Power, close out on the week that was 13/03/2020. They run through a number of announcements from over the week and share a market wrap on what was one of the sharpest weekly declines in recent years.
SomnoMed (ASX:SOM) Chief Executive Officer Neil Verdal-Austin, joins Morgans Research Analyst Iain Wilkie to discuss the company's 1H20 results, and share some insight into what to expect in the next 12 months.
Morgans Analyst Iain Wilkie and Senior Analyst Scott Power, close out on the week that was 6/03/2020. They share an update on the latest research surrounding the coronavirus and run through a couple of stocks to look out for.
Morgans Analyst Iain Wilkie, close out on the week that was 28/02/2020. Providing a rundown of the ASX listed healthcare index, outlining some key catalysts to look forward to, and list a number of names to watch out for.
Morgans Analyst Iain Wilkie and Senior Analyst Scott Power, close out on the week that was 21/02/2020. Providing a rundown of the ASX listed healthcare index, outlining some key catalysts to look forward to, and list a number of names to watch out for.
Morgans Senior Analyst Scott Power shares a Mid-Reporting Season update on the healthcare sector.
Scott discusses 1H results for CSL (CSL), Cochlear (COH), Ansell (ANN), Promedicus (PME), ResMed (RMD) and Virtus Health (VRT).
He also shares his views on Sonic Healthcare (SHL), Mach 7(M7T), Nanosonics (NAN), Volpara Health Technologies (VHT) and Paradigm Biopharma (PAR) who are yet to release their 1H results.
Morgans Analyst Iain Wilkie and Senior Analyst Scott Power, close out on the week that was 14/02/2020. Providing a rundown of the ASX listed healthcare index, outlining some key catalysts to look forward to, and list a number of names to watch out for.
ResApp Health’s (ASX:RAP) Managing Director, and Chief Executive Officer, Dr. Tony Keating provides an update on the company’s progress.
Morgans Analyst Iain Wilkie close out on the week that was 07/02/2020. Providing a rundown of the ASX listed healthcare index, outlining some key catalysts to look forward to, and list a number of names to watch out for.
Morgans analysts Scott Power and Iain Wilkie close out on the previous week that was 31/01/2020. The boys provide a rundown of the ASX listed healthcare index, outlining some key catalysts to look forward to, and list a number of names to watch out for.
Mike Lampron, Managing Director of Mach7 (ASX:M7T) provided an update on its business to the Morgans network.
Morgans analysts Scott Power and Iain Wilkie close out another week with a rundown of the ASX listed healthcare index, outline some key catalysts to look forward to, and list a number of names to watch out for.
Morgans Analyst Iain Wilkie chats to Sean Hall, CEO of Medlab (MDC) to update progress on the company and its clinical programs.
Morgans analysts Scott Power and Iain Wilkie close out another week with a rundown of the ASX listed healthcare index, outline some key catalysts to look forward to, and list a number of names to watch out for.
Morgans analysts Scott Power and Iain Wilkie close out another week with a rundown of the ASX listed healthcare index, outline some key catalysts to look forward to, and list a number of names to watch out for, heading into the quarterly reporting.
Morgans Senior Analysts Derek Jellinek and Scott Power discuss Sonic Healthcare (ASX:SHL), ResMed (ASX:RMD), Volpara (ASX:VHT) and Pro Medicus (ASX:PME), which are all on our best buy list for January 2020.
Healthcare wrap up for week ending 3 January 2020. Stocks mentioned Opthea (OPT), Volpara (VHT), Somnomed (SOM), ResApp (RAP), Medlab (MDC).
Dr Derek Jellinek provides feedback from a major radiology conference (RSNA) in Chicago
Morgans Senior Analyst Scott Power, and Research Analyst Iain Wilkie sneak in another episode of Under the Microscope before year-end. In this episode, the boys comment on a number of key announcements over the week and also their key picks for 2020. Featured companies include Antisense Therapeutics (ASX:ANP), Medlab Clinical (ASX: MDC), Volpara (ASX:VHT), Pro Medicus (ASX:PME), ResApp (ASX:RAP), and Opyl (ASX:OPL).
Follow some further updates on their Twitter account @MorgansHealthc1.
Listen to the full podcast here!
Dr Derek Jellinek provides feedback on Mach 7 after meeting them at a radiology conference in Chicago.
Morgans Senior Analyst Scott Power, and Research Analyst Iain Wilkie close the week with another episode of Under the microscope, the last on PODCAST for 2019. In this episode, the boys comment on key movements in the healthcare space and highlight a recent institutional placement in 1st Group (ASX:1ST). They’ve also started up a twitter account @MorgansHealthc1 so followers can keep updated.
Also a reminder of the most recent PODCAST of the series with: Michelle Gallaher from Opyl (ASX:OPL) and Tony Keating from ResApp (ASX:RAP).
Tony Keating CEO of ResApp Health outlines a number of key near-term milestones for investors to focus on.
Michelle Gallaher CEO of Opyl (ASX:OPL) explains how the company is positioning itself to growth in the digital healthcare sector.
Morgans Senior Analyst Scott Power, and Research Analyst Iain Wilkie close the week with another episode of Under the microscope. In this episode, the boys comment on key movements in the healthcare space including Iains comments on the latest in the Medical Cannabis space. Featured companies include Volpara (ASX:VHT), Pro Medicus (ASX:PME), Mach7 (ASX:M7T), Cann Group (ASX:CAN), THC Global Group (ASX:THC), Zelira Therapeutics (ASX:ZLD), Antisense Therapeutics (ASXANP) and the newly consolidated Opal Horizon (ASX:OHZ). Listen to the full podcast here!
Scott Power Morgans Senior Analyst speaks on the CSL R&D day and updates on feedback from a major radiology conference in Chicago where Volpara, Promedicus, and Mach 7 are being represented.
Morgans Senior Analyst Scott Power, closes the week with another episode of Under the microscope. In this episode, Scott comments on key movements in companies SomnoMed (ASX:SOM), Volpara Health Technologies (ASX:VHT) and Pro Medicus (ASX:PME). Listen to the full podcast here!
Matthew Liddelow, Chief Executive Officer and Managing Director of NeuroScientific Biopharmaceuticals (ASX:NSB) was interviewed by Morgans Senior Analyst Scott Power. Matthew detailed NSB as a company as well as their position heading into the next 12 months.
Morgans Senior Analyst Scott Power, and Research Analyst Iain Wilkie close the week with another episode of Under the microscope. In this episode, the boys comment on key movements within the Healthcare sector wrapping the week that was - week ending in 22 November 2019.
Scott Power Morgans Senior Analyst discusses Pro Medicus part of the Morgans Best Ideas (November 2019).
Mike Harsh - Non-Executive Director of Imagion Biosystems (IBX) talks about what attracted him to the company.
Mike Harsh (former CTO of GE Healthcare and the current non-executive director of Imagion Biosystems (IBX)) talks about the changing imaging landscape.
Morgans Healthcare Team with a wrap of the movers and shakers in the Healthcare sector.
ShareRoot's CEO Michelle Gallaher provides an update on the turnaround of the business to the Morgans network.
Anatara Lifescience (ANR): CEO Steven Lydeamore updates the Morgans network on the company's progress
Dr Ralph Highnam CEO of Volpara Health Technologies (ASX:VHT) presented to the Morgans network.
Morgans Senior Analyst Scott Power spoke to Dr Bill Ketelbey CEO of Actinogen Medical (ASX:ACW)who explains recent clinical trial results and the path forward
Morgans Healthcare Team with a wrap of the movers and shakers in the Healthcare sector.
Morgans Healthcare Team with a wrap of the movers and shakers in the Healthcare sector.
Under the Microscope looking for opportunities in a volatile market ... a wrap for the week ended 4th October 2019.
Clayton Hatch, Chief Financial Officer of Pro Medicus (ASX:PME) discussed their company result for FY19 with the Morgans network.